Drug intelligence / Profile preview

ORCA

Development stage: Unknown
Lead developer: aTyr Pharma
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

ORCA was a preclinical program developed by aTyr Pharma, a biotherapeutics company focused on Physiocrine-based therapeutics. This program aimed to develop antibodies to target a novel, proprietary immuno-oncology pathway, specifically the Resokine pathway, to enhance the immune response in tumor settings. The Resokine pathway is comprised of extracellular proteins derived from the histidyl tRNA synthetase (HARS) gene family. The program was discontinued in May 2018 due to preclinical data not showing sufficient efficacy to warrant further development.

Targets

aaRS (Aminoacyl-tRNA synthetase family)

Beyond the preview

Go deeper on ORCA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORCA.

Explore the full profile